<level type="section">
  <num>28-4552</num>
  <heading>Definitions.</heading>
  <text>For the purposes of this chapter, the term:</text>
  <level>
    <level>
      <num>(1)</num>
      <text>"Affected party" means any person directly or indirectly affected by excessive prices of patented prescription drugs, including any organization representing such persons or any person or organization representing the public interest.</text>
    </level>
    <level>
      <num>(2)</num>
      <text>"High income country" means the United Kingdom, Germany, Canada, or Australia.</text>
    </level>
  </level>
  <level>
    <type>annotations</type>
    <level>
      <heading>CREDIT(S)</heading>
      <text>(Dec. 10, 2005, D.C. Law 16-37, ยง 2, 52 DCR 9061.)</text>
      <text>GENERAL NOTES</text>
      <text>
        <text i="True">This chapter has been held unconstitutional in the case of Pharmaceutical Research and Mfrs. of America v. District of Columbia, 2005, 406 F.Supp.2d 56, 78 U.S.P.Q.2d 1822, affirmed 496 F.3d 1362, 83 U.S.P.Q.2d 1639, rehearing and rehearing en banc denied 505 F.3d 1343, 85 U.S.P.Q.2d 1144.</text>
      </text>
    </level>
    <level>
      <heading>HISTORICAL AND STATUTORY NOTES</heading>
      <level>
        <heading>Legislative History of Laws</heading>
        <text>For Law 16-37, see notes following ยง 28-4551.</text>
      </level>
    </level>
  </level>
</level>
